(Adnkronos) - Farmaco a mRNA dimezza i livelli di colesterolo con iniezioni semestrali. Sono i risultati dello studio CHOLINET, coordinato dal professore Perrone Filardi sull’impiego di Inclisiran: una riduzione del colesterolo LDL del 60%.
Category
🗞
NewsTranscript
00:00The management of hypercholesterolemia is fundamental for the prevention of cardiovascular diseases,
00:09one of the main causes of mortality on a global level.
00:12However, a persistent problem in the therapy against cholesterol is the adherence of patients to prescribed therapeutic regimes.
00:19Recently, the emergence of the Inclisiran drug, supported by the results of the Colinet study conducted by Professor Perrone Filardi,
00:27Director of the Department of Advanced Biomedical Sciences of the Federico II University of Naples,
00:32opened new perspectives to improve adherence to therapy in subjects who have already had an acute cardiovascular event,
00:38or with atherosclerotic disease in various districts, diabetics at cardiovascular risk and subjects with family hypercholesterolemia.
00:46The new drugs for the control of dyslipidemia, that is cholesterol and LDL,
00:51and in particular the drug-object of our study, which is called Inclisiran,
00:57are particularly important because they have a new mechanism of action, they are very effective,
01:02they are devoid of side effects and give an important adherence duration.
01:08Using RNA-interfering technology, Inclisiran silences a specific gene in the liver,
01:15thus reducing the production of LDL cholesterol, with an evident effectiveness and tolerance of the drug.
01:22LDL cholesterol is reduced by 51% in 3 months and even more than 60% in 9 months.
01:36This is especially true when, together with Inclisiran, there is also a substantive statin.
01:45Another important fact is that out of 650 patients, only 23, for various reasons, have abandoned the drug,
01:55never for important side effects, unfortunately, or in most cases,
02:02because their doctor believed that the added value of cholesterol was too low.
02:07We insist on saying that there is no value of cholesterol too low.
02:11Unlike traditional treatments that require daily assumptions,
02:15one of the main advantages of Inclisiran is its supply regime,
02:19which not only simplifies the therapeutic process, but also improves the adherence of patients.
02:25The adherence, which means that the patient maintains the therapy as prescribed by the doctor,
02:33was 93-94%.
02:36On the other hand, we explain it to ourselves, because these are drugs without side effects.
02:43The supply, so distanced over time, is very convenient for the patient,
02:49it does not involve particular precautions, even in terms of drug maintenance,
02:58of drug treatment at home.
03:05So it's a very simple thing that can be done, and this explains this high adherence.
03:11The new adherence to cholesterol therapy is a crucial challenge in the fight against cardiovascular diseases
03:17in a reimbursability regime for patients selected through simple processes and key steps.
03:24By addressing their specialist, but also their general medicine doctor,
03:28certainly the colleagues of the general medicine are well informed about this therapy
03:34and will be able to direct patients to the reference centers,
03:37where they are authorized to prescribe and formulate the therapeutic plan for reimbursability.
03:44With the advancement of research in the field of pharmacological therapy,
03:49and in particular of pharmacological and cardiovascular therapies,
03:53today we have injectable drugs that are extremely comfortable for the patient,
03:58extremely beneficial and extremely effective.